Soleno Therapeutics (SLNO) Depreciation & Amortization (CF) (2013 - 2026)
Soleno Therapeutics (SLNO) posted quarterly Depreciation & Amortization (CF) of $514000.0 for Q1 2026, up 1.98% year-over-year from $504000.0 in Q1 2025, and up 0.98% quarter-over-quarter from $509000.0 in Q4 2025.
Soleno Therapeutics (SLNO) Depreciation & Amortization (CF) (2013 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Depreciation & Amortization (CF) for 14 consecutive years, with $514000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 1.98% year-over-year to $514000.0; the TTM figure through Mar 2026 stood at $2.0 million (up 1.3% YoY), while the FY2025 annual figure was $2.0 million, up 1.51% from the prior year.
- Depreciation & Amortization (CF) rose to $514000.0 in Q1 2026 per SLNO's latest filing, from $509000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $514000.0 in Q1 2026 and bottomed at $488000.0 in Q4 2022.
- Historically, Depreciation & Amortization (CF) has averaged $496470.6 across 5 years, with a median of $492000.0 in 2022.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) fell 0.81% — and 2024, when it advanced 2.86%.
- Soleno Therapeutics' Depreciation & Amortization (CF) stood at $488000.0 in 2022, then increased by 0.2% to $489000.0 in 2023, then advanced by 2.86% to $503000.0 in 2024, then increased by 1.19% to $509000.0 in 2025, then advanced by 0.98% to $514000.0 in 2026.
- Business Quant data shows SLNO's Depreciation & Amortization (CF) at $514000.0 in Q1 2026, $509000.0 in Q4 2025, and $502000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn | 514,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 514,000.00 |
| Mar 31, 2026 | 514,000.00 |
| Dec 31, 2025 | 509,000.00 |
| Dec 31, 2025 | 509,000.00 |
| Sep 30, 2025 | 502,000.00 |
| Sep 30, 2025 | 502,000.00 |
| Jun 30, 2025 | 502,000.00 |
| Jun 30, 2025 | 502,000.00 |
| Mar 31, 2025 | 504,000.00 |
| Mar 31, 2025 | 504,000.00 |
| Dec 31, 2024 | 503,000.00 |
| Dec 31, 2024 | 503,000.00 |
| Sep 30, 2024 | 500,000.00 |
| Sep 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 494,000.00 |
| Jun 30, 2024 | 494,000.00 |
| Mar 31, 2024 | 490,000.00 |
| Mar 31, 2024 | 490,000.00 |
| Dec 31, 2023 | 489,000.00 |
| Dec 31, 2023 | 489,000.00 |